Skip to Main Content
Advertisement
Close
The Journal of Immunology
ImmunoHorizons
Collections
AAI.ORG
FAQs
Predatory Publishing FAQ
Site FAQ
Publishing Partnership FAQ
Reduced Author Fees FAQ
Search Dropdown Menu
header search
search input
Search input auto suggest
filter your search
All Content
The Journal of Immunology
Search
Advanced Search
User Tools Dropdown
Register
Sign In
Toggle Menu
Menu
Articles
Current Issue
Next in The JI
Archive
Brief Reviews
Translating Immunology
Pillars of Immunology
COVID-19, SARS, and MERS Articles
Monkeypox and Other Poxvirus Articles
Annual Meeting Abstracts
About the JI
About the JI
Journal Policies
Alerts
Authors
Submit
Instructions for Authors
Journal Policies
Editors
The JI Editorial Board
ImmunoHorizons
Subscriptions
Subscribe
Members
Librarians
FAQs
Predatory Publishing FAQ
Site FAQ
Publishing Partnership FAQ
Reduced Author Fees FAQ
Skip Nav Destination
Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors
J Immunol
(2023) 211 (2): 295–305.
Currently there are no citedby results. Try again later.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to
our privacy policy.
Accept
